Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease hypercalcemia
Phenotype C0026764|multiple myeloma
Sentences 10
PubMedID- 24743202 Bisphosphonates(bps)have been widely used for the treatment of hypercalcemia associated with cancer, multiple myeloma bone diseases, and bone metastasis of solid cancers.
PubMedID- 25128013 Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction.
PubMedID- 23571233 These drugs are used in the treatment of osteoporosis, paget's disease, hypercalcaemia associated with malignancy, multiple myeloma, etc.
PubMedID- 21605111 Calciphylaxis, occurring 10 weeks after hypercalcaemia, in a patient with multiple myeloma.
PubMedID- 21915243 Interestingly, aminobisphosphonates (abs) which are synthetic compounds commonly used to treat bone disease and hypercalcemia in patients with multiple myeloma, breast or prostate cancer, have been identified also as antigens for γδ t cells, indicating these molecules as immunomodulating factors [21]–[26].
PubMedID- 26500541 hypercalcemia in multiple myeloma may be the result of bone marrow infiltration and release of osteoclast-activating factors by the plasma cells [3].
PubMedID- 22073517 multiple myeloma with hypercalcemia and chloride resistant metabolic alkalosis.
PubMedID- 22082730 Introduction: osteonecrosis of the jaw (onj) is an emerging condition in patients undergoing long-term administration of bisphosphonates (bp) for the treatment of osteoporosis and hypercalcaemia associated with malignancy, multiple myeloma, and metastatic breast and prostate cancers.
PubMedID- 24334568 It is the most common primary bone malignancy, and the extensive osteoclastic bone resorption common in multiple myeloma is associated with hypercalcemia in as many as one-third of patients.
PubMedID- 23700375 After the diagnosis of multiple myeloma with hypercalcemia, specific treatment was instigated, according to the following protocol (figure 2): intravenous normal saline (na, 154 mmol/l; cl, 154 mmol/l; 500 ml × 2/day; daily), dexamethasone (8 mg per day × 2 consecutive days), nahco3 (80 mmol/l per day; daily), bortezomib (1.3 mg/m2 per dose, weekly), elcatonin (40 units per day for 5 consecutive days), and zoledronic acid hydrate (4 mg per dose, monthly).

Page: 1